In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Executive Summary

Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.

Related Content

What New Cancer Pathway Programs Mean For The Drug Industry
A Look Back At 2010: In Search Of New Biopharma Models
NPS Pharmaceuticals Stages A Second Act
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Pharma: Serious About Change?
Why Doesn't Pharma Get Smaller?
Why Doesn't Pharma Get Smaller?
Novartis's Research Experiment
Novartis's Research Experiment
Shire: Remodeling Specialty Pharma


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts